These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34986854)

  • 21. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
    Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
    Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Full GMP-compliant validation of bone marrow-derived human CD133(+) cells as advanced therapy medicinal product for refractory ischemic cardiomyopathy.
    Belotti D; Gaipa G; Bassetti B; Cabiati B; Spaltro G; Biagi E; Parma M; Biondi A; Cavallotti L; Gambini E; Pompilio G
    Biomed Res Int; 2015; 2015():473159. PubMed ID: 26495296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interpretation of transplant biopsies and immune responses following Treg cell therapy.
    Tang Q; Kang SM
    Curr Opin Organ Transplant; 2014 Dec; 19(6):616-20. PubMed ID: 25313874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy.
    Fritsche E; Volk HD; Reinke P; Abou-El-Enein M
    Trends Biotechnol; 2020 Oct; 38(10):1099-1112. PubMed ID: 31982150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory T Cells for the Induction of Transplantation Tolerance.
    Que W; Li XK
    Adv Exp Med Biol; 2021; 1278():289-302. PubMed ID: 33523454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.
    Putnam AL; Safinia N; Medvec A; Laszkowska M; Wray M; Mintz MA; Trotta E; Szot GL; Liu W; Lares A; Lee K; Laing A; Lechler RI; Riley JL; Bluestone JA; Lombardi G; Tang Q
    Am J Transplant; 2013 Nov; 13(11):3010-20. PubMed ID: 24102808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.
    Haase D; Starke M; Puan KJ; Lai TS; Rotzschke O
    Immunol Res; 2012 Sep; 53(1-3):200-12. PubMed ID: 22418725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical-Grade-Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell-Dependent Graft-versus-Leukemia Effect in Murine Models.
    Del Papa B; Ruggeri L; Urbani E; Baldoni S; Cecchini D; Zei T; Iacucci Ostini R; Crescenzi B; Carotti A; Pierini A; Sportoletti P; Di Bartolomeo P; Falzetti F; Mecucci C; Velardi A; Martelli MF; Di Ianni M
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1847-1851. PubMed ID: 28729148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35.
    Ulbar F; Villanova I; Giancola R; Baldoni S; Guardalupi F; Fabi B; Olioso P; Capone A; Sola R; Ciardelli S; Del Papa B; Brattelli A; Ricciardi I; Taricani S; Sabbatinelli G; Iuliani O; Passeri C; Sportoletti P; Santarone S; Pierini A; Calabrese G; Falzetti F; Bonfini T; Accorsi P; Ruggeri L; Martelli MF; Velardi A; Di Ianni M
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2204-2210. PubMed ID: 32961369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ex vivo-expanded highly pure ABCB5
    Kerstan A; Niebergall-Roth E; Esterlechner J; Schröder HM; Gasser M; Waaga-Gasser AM; Goebeler M; Rak K; Schrüfer P; Endres S; Hagenbusch P; Kraft K; Dieter K; Ballikaya S; Stemler N; Sadeghi S; Tappenbeck N; Murphy GF; Orgill DP; Frank NY; Ganss C; Scharffetter-Kochanek K; Frank MH; Kluth MA
    Cytotherapy; 2021 Feb; 23(2):165-175. PubMed ID: 33011075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis.
    Voskens CJ; Fischer A; Roessner S; Lorenz C; Hirschmann S; Atreya R; Neufert C; Atreya I; Neurath MF; Schuler G
    Inflamm Bowel Dis; 2017 Aug; 23(8):1348-1359. PubMed ID: 28708802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.
    Hannon M; Lechanteur C; Lucas S; Somja J; Seidel L; Belle L; Bruck F; Baudoux E; Giet O; Chantillon AM; Delvenne P; Drion P; Beguin Y; Humblet-Baron S; Baron F
    Transfusion; 2014 Feb; 54(2):353-63. PubMed ID: 23772685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical-grade regulatory T cells: Comparative analysis of large-scale expansion conditions.
    Velaga S; Alter C; Dringenberg U; Thiesler CT; Kuhs S; Olek S; Ukena SN; Franzke A
    Exp Hematol; 2017 Jan; 45():27-35.e1. PubMed ID: 27693388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.
    Johanna I; Daudeij A; Devina F; Nijenhuis C; Nuijen B; Romberg B; de Haar C; Haanen J; Dolstra H; Bremer E; Sebestyen Z; Straetemans T; Jedema I; Kuball J
    Immunooncol Technol; 2023 Dec; 20():100411. PubMed ID: 38192616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases.
    Mebarki M; Iglicki N; Marigny C; Abadie C; Nicolet C; Churlaud G; Maheux C; Boucher H; Monsel A; Menasché P; Larghero J; Faivre L; Cras A
    Stem Cell Res Ther; 2021 Nov; 12(1):571. PubMed ID: 34774107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treg therapy in transplantation: a general overview.
    Romano M; Tung SL; Smyth LA; Lombardi G
    Transpl Int; 2017 Aug; 30(8):745-753. PubMed ID: 28012226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol.
    MacDonald KN; Ivison S; Hippen KL; Hoeppli RE; Hall M; Zheng G; Dijke IE; Aklabi MA; Freed DH; Rebeyka I; Gandhi S; West LJ; Piret JM; Blazar BR; Levings MK
    Cytotherapy; 2019 Dec; 21(12):1216-1233. PubMed ID: 31810768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells.
    Theil A; Wilhelm C; Kuhn M; Petzold A; Tuve S; Oelschlägel U; Dahl A; Bornhäuser M; Bonifacio E; Eugster A
    Clin Exp Immunol; 2017 Feb; 187(2):316-324. PubMed ID: 27774628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model.
    Issa F; Hester J; Milward K; Wood KJ
    PLoS One; 2012; 7(12):e53331. PubMed ID: 23300911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.